The Core Peptides copyright Diaries
Therapeutic vaccine candidates applying viral vectors encoding LMP2 have effectively induced virus-precise CD8⁺ T mobile responses in early-section clinical trials. Furthermore, adoptive T cell therapies like posoleucel also goal LMP2 along with other latency proteins including EBNA1, reinforcing its significance for a conserved and immunodominan